NASDAQ:BMRA - Biomerica Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.50 -0.10 (-3.85 %)
(As of 12/17/2018 02:19 PM ET)
Previous Close$2.60
Today's Range$2.44 - $2.50
52-Week Range$2.39 - $9.32
Volume92 shs
Average Volume15,542 shs
Market Capitalization$23.49 million
P/E Ratio-14.59
Dividend YieldN/A
Beta-0.13
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. It operates in Europe, the United States, Asia, South America, the Middle East, and internationally. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BMRA
Previous Symbol
CUSIPN/A
Phone949-645-2111

Debt

Debt-to-Equity RatioN/A
Current Ratio5.20
Quick Ratio2.42

Price-To-Earnings

Trailing P/E Ratio-14.59
Forward P/E Ratio-10.87
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.56 million
Price / Sales4.06
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.50 per share
Price / Book5.00

Profitability

EPS (Most Recent Fiscal Year)($0.17)
Net Income$-1,460,000.00
Net Margins-31.75%
Return on Equity-41.73%
Return on Assets-34.79%

Miscellaneous

Employees39
Outstanding Shares9,030,000
Market Cap$23.49 million
OptionableNot Optionable

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) posted its earnings results on Tuesday, October, 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The business had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.38 million. Biomerica had a negative net margin of 31.75% and a negative return on equity of 41.73%. View Biomerica's Earnings History.

When is Biomerica's next earnings date?

Biomerica is scheduled to release their next quarterly earnings announcement on Tuesday, January 15th 2019. View Earnings Estimates for Biomerica.

What price target have analysts set for BMRA?

1 equities research analysts have issued 1 year target prices for Biomerica's shares. Their forecasts range from $6.25 to $6.25. On average, they expect Biomerica's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 150.0% from the stock's current price. View Analyst Price Targets for Biomerica.

What is the consensus analysts' recommendation for Biomerica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biomerica.

Has Biomerica been receiving favorable news coverage?

Headlines about BMRA stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biomerica earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are some of Biomerica's key competitors?

Who are Biomerica's key executives?

Biomerica's management team includes the folowing people:
  • Mr. Zackary S. Irani, Chairman & CEO (Age 52)
  • Mr. Francis E. Capitanio, Pres (Age 74)
  • Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 67)

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $2.50.

How big of a company is Biomerica?

Biomerica has a market capitalization of $23.49 million and generates $5.56 million in revenue each year. The company earns $-1,460,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Biomerica employs 39 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is http://www.biomerica.com.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.


MarketBeat Community Rating for Biomerica (NASDAQ BMRA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote "Outperform" if you believe BMRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel